Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

Por Passaro A, Lazzari C, Karachaliou N, Spitaleri G, Pochesci A, Catania C, Rosell R, de Marinis F
Publicado em 2016-10-01

Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma

Por De Pas, T, Spitaleri, G, Vigna, PD, Toffalorio, F, Curigliano, G, Gambino, A, Boselli, S, Catania, C, de Braud, F
Publicado em 2008

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

Por Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T
Publicado em 2015-08-01

QTc prolongation assessment in anticancer drug development: clinical and methodological issues

Por Curigliano, G, Spitaleri, G, de Braud, F, Cardinale, D, Cipolla, C, Civelli, M, Colombo, N, Colombo, A, Locatelli, M, Goldhirsch, A
Publicado em 2009

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

Por Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, De Pas TM
Publicado em 2014-05-01

Gene expression profiling reveals GC and CEACAM1 as new tools in the diagnosis of lung carcinoids

Por Toffalorio, F, Belloni, E, Barberis, M, Bucci, G, Tizzoni, L, Pruneri, G, Fumagalli, C, Spitaleri, G, Catania, C, Melotti, F, Pelicci, P G, Spaggiari, L, De Pas, T
Publicado em 2014